An information-theoretical approach was used to identify prognostic factors for survival in patients with estrogen receptor-positive (ER D ) breast cancer and to classify those patients according to the prognostic factors. We demonstrated that KMT2C and SLC20A1 are powerful prognostic biomarkers in ER D breast cancer that can distinguish patients with an extremely bad prognosis from those with a sufficiently good prognosis at the time of breast cancer diagnosis. Introduction: In general, it has been considered that estrogen receptor-positive (ER þ ) breast cancer has a good prognosis and is responsive to endocrine therapy. However, one third of patients with ER þ breast cancer exhibit endocrine therapy resistance, and many patients develop recurrence and die 5 to 10 years after diagnosis. In ER þ breast cancer, a major problem is to distinguish those patients most likely to develop recurrence or metastatic disease within 10 years after diagnosis from those with a sufficiently good prognosis. Materials and Methods: We downloaded the messenger RNA expression data and the clinical information for 401 patients with ER þ breast cancer from the cBioPortal for Cancer Genomics. An information-theoretical approach was used to identify the prognostic factors for survival in patients with ER þ breast cancer and to classify those patients according to the prognostic factors. Results: The information-theoretical approach contributed to the identification of KMT2C and SLC20A1 as prognostic biomarkers in ER þ breast cancer. We found that low KMT2C expression was associated with a poor outcome and high SLC20A1 expression was associated with a poor outcome. Both levels of KMT2C and SLC20A1 expression were significantly and strongly associated with the differentiation of survival. The 10-year survival rate for ER þ patients with low KMT2C and high SLC20A1 expression was 0%. In contrast, for ER þ patients with high KMT2C
Introduction
Breast cancer is one of the most common cancers worldwide, with nearly 1.7 million new cases (25% of all cancers in women) and 0.5 million cancer deaths (15% of all cancer deaths in women) in 2012 according to the estimate from the International Agency for Research on Cancer. 1 Breast cancer is a highly heterogeneous disease, with different biologic features, clinical outcomes, and treatment responses. 2, 3 Therefore, it is important to consider a clinically and scientifically meaningful classification of the disease. Breast cancer has been classified into biologic subtypes using immunohistochemistry for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. [2] [3] [4] [5] [6] [7] [8] Of these subtypes, ER þ breast cancer accounts for 70% to 80% of all diagnosed breast tumors. 6, 8 In general, it is considered that ER þ breast cancer has a good prognosis and is responsive to endocrine therapy. 6, 8, 9 However, one third of patients with ER þ breast cancer will exhibit endocrine therapy resistance, 6 and many patients with ER þ breast cancer develop recurrence and die 5 to 10 years after diagnosis. 10, 11 An urgent need exists to reduce the recurrence and mortality rates during the 5 to 10 years after the breast cancer diagnosis for ER þ disease. In addition, breast cancer can be classified into the gene expression-based "intrinsic" subtypes known as luminal A, luminal B, Her2-enriched, and basallike. 4 The PAM50 gene set is the standard for identifying "intrinsic"
subtypes. 12 Most luminal-type breast cancers are ER þ tumors. 12, 13 ER þ luminal breast cancers have been reported to be the most heterogeneous in terms of gene expression, mutation spectrum, copy number changes, and clinical outcomes. 14 In ER þ breast cancer, a major problem is to distinguish those patients most likely to develop recurrence or metastatic disease within 10 years after breast cancer diagnosis from those with a sufficiently good prognosis. This has brought into sharp relief the need for new prognostic markers that can predict the outcome as accurately as possible at the diagnosis.
In information theory, information is quantified using the concept of uncertainty. 15 We are interested in how the concept of uncertainty is related to the understanding of life phenomena. Several recent studies have given some ideas on the application of mathematics in quantum information theory to biosystems and life sciences. [15] [16] [17] In the present study, we adopted an information-theoretical approach to identify prognostic factors for survival in patients with ER þ breast cancer and to classify those patients according to the prognostic factors. The uncertainty in the prognosis of patients with ER þ breast cancer is remarkably large; however, the uncertainty can be reduced by gene expression information. Using this approach. we identified KMT2C and SLC20A1 as prognostic biomarkers in ER þ breast cancer.
Materials and Methods

Data Set
We used the TCGA Nature 2012 data set 14 deposited in cBioPortal. 18, 19 The data set contains 526 primary breast tumor samples (patients) with messenger RNA (mRNA) expression data. Of these 526 patients, 401 were ER þ patients. We downloaded the mRNA expression Z-scores of genes in the 2 gene sets and the clinical information for the 401 patients from the cBioPortal. For the first gene set, we used 70 "recurrently mutated genes" provided by cBioPortal. We filtered out genes with missing information on mRNA expression, which gave us mRNA expression Z-scores for 60 genes. For the second gene set, we used 1918 intrinsic genes described by Parker et al. 2 We filtered out genes not available on cBioPortal, which resulted in mRNA expression Z-scores for 1647 genes. The overlap between the 2 gene sets was 15 genes.
Information-theoretical Analysis
To identify the prognostic factors for survival in patients with ER þ breast cancer, an information-theoretical approach was used.
We define the following 4 events to measure the uncertainty in prognosis: (x 1 ), death within 5 years after diagnosis; (x 2 ), death within 5 to 10 years after diagnosis; (x 3 ), survival for ! 5 to 10 years after diagnosis; (x 4 ), survival > 10 years after diagnosis. The probabilities of these 4 events are given by p(x 1 ), p(x 2 ), p(x 3 ), p(x 4 ), respectively. In the case in which P 4 i ¼ 1 pðx i Þ ¼ 1, the complete event system X is determined as follows:
The Shannon entropy of the complete event system X is defined as
which gives a measure of the uncertainty of X and takes from a minimum value of 0 to a maximum value of log4 ¼ 2.0 (log denotes the binary logarithm throughout this report). The entropy S(X ) takes 0 when an event occurs with a probability of 1 and takes log4 when all events occur with an equal probability of 1 of 4. We used this measure to quantify uncertainty in the prognosis of patients with ER þ breast cancer.
Moreover, we define the following 2 events for the mRNA expression levels of a gene: (y 1 ), Z-score > 0 (high); (y 2 ), Zscore < 0 (low). The complete event system Y is denoted by the probability p(y 1 ) of (y 1 ) and the probability p(y 2 ) of y 2 such that p(y 1 ) þ p(y 2 ) ¼ 1 as follows:
In practice, using the mRNA expression Z-scores of each gene contained in the first gene set and the second gene set, the complete event system Y for the mRNA expression levels of each gene can be determined.
The compound event system X Â Y for X and Y is denoted by the joint probability p(x i ,y j ) for the event x i (i ¼ 1,2,3,4) of X and the event y j ( j¼1,2) of Y, which satisfy P j pðx i ; y j Þ ¼ pðx i Þ and P i pðx i ; y j Þ ¼ pð y j Þ. Using these event systems, the mutual information is defined as
which is non-negative. A basic property of the mutual information is that I ðX ; Y Þ ¼ SðX Þ À SðX jY Þ, where SðX jY Þ is the conditional entropy. Thus, the mutual information measures the reduction in uncertainty of X due to the knowledge of Y. Larger mutual information implies less uncertainty in X. When the mutual information is large, the 2 systems X and Y, correlate highly. In contrast, when the mutual information is 0, the 2 systems will be uncorrelated (ie, the 2 systems will be independent). Accordingly, in the present study, finding genes that lead to large mutual information suggests the presence of potential prognostic biomarkers in ER þ breast cancer.
In addition, to evaluate the association between patient survival and mRNA expression of specific genes identified from the information-theoretical analysis, Kaplan-Meier plots and the logrank test were used.
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Results
Most of the 401 patients with ER þ breast cancer were censored within the first 5 years after diagnosis. Therefore, the informationtheoretical approach we have reported was used in 78 ER þ patients.
Of the 78 ER þ patients, 23 patients had died within 5 years after diagnosis, 18 patients had died within 5 to 10 years, 27 patients had survived for ! 5 to 10 years, and 10 patients had survived > 10 years. The complete event system X was determined by their occurrence probabilities, and the Shannon entropy of X was 1.91743. In addition, the 78 ER þ patients were divided into high and low groups based on the mRNA expression Z-scores of each gene contained in the first gene set and the second gene set. The complete event system Y for each gene's mRNA expression levels was determined by their occurrence probabilities, and then the compound event system expressing the relation between X and Y was determined. The mutual information between X and Y for each of the 60 genes in the first gene set is presented in Supplemental Table 1 (available in the online version). The mutual information between X and Y for each of the 1647 genes in the second gene set is presented in Supplemental Table 2 (available in the online version).
The genes were ranked on the basis of their mutual information. KMT2C was ranked first among the first gene set, and SLC20A1 was ranked first among the second gene set. The mutual information for the expression of KMT2C and SLC20A1 was 0.15206 (Table 1 ) and 0.21321 (Table 2) . Of the 78 ER þ patients, 65 had luminal-type breast cancer. When the 65 cases were divided into luminal A and luminal B, as described in Table 3 , the Shannon entropy was 1.91443, and the mutual information was 0.05327. From their mutual information, we can show how the uncertainty in the prognosis of patients with ER þ breast cancer can be reduced using the KMT2C and SLC20A1 expression information. The expression information of KMT2C and SLC20A1 is worth 3 or 4 times as much as the subtype information (luminal A and luminal B) by simple calculation. Using the expression levels of KMT2C and SLC20A1, which were selected using the information-theoretical approach, the survival of the entire group of 401 patients with ER þ breast cancer was examined by the Kaplan-Meier estimation ( Figure 1 ). As expected, the expression of KMT2C and SLC20A1 was significantly associated with the degree of difference in survival. Of the 401 ER þ patients, 207 had high expression of KMT2C
and 194 low expression of KMT2C. As seen in Figure 1A , patients with low KMT2C expression had significantly worse overall survival compared with patients with high KMT2C expression (log-rank, P ¼ .0005). The 10-year survival rate for patients with high KMT2C versus low KMT2C expression was 66.34% versus 21.13%, respectively. Of the 401 ER þ patients, 210 had high and 191 had low SLC20A1 expression. As seen in Figure 1B , patients with high SLC20A1 expression had significantly worse overall survival than patients with low SLC20A1 expression (P ¼ .0022). The 10-year survival rate for patients with high SLC20A1 versus low SLC20A1 expression was 17.16% versus 68.45%, respectively. In contrast, for the 344 patients with luminal subtypes of the 401 ER þ patients, the 10-year survival rate was 50% for patients with the luminal A subtype and 32% for patients with the luminal B subtype, respectively. Of the 344 patients, 220 had the luminal A subtype and 124 the luminal B subtype. Table 4 shows their survival rates at 5 and 10 years after the breast cancer diagnosis estimated using Kaplan-Meier methods. In addition, we defined 4 events for the complete event system Y. When the 78 patients with ER þ breast cancer were divided into high/high, high/low, low/high, and low/low KMT2C/SLC20A1 expression (Table 5) , the mutual information was 0.39518. The Kaplan-Meier survival curves for the entire group of 401 patients with ER þ , stratified by KMT2C and SLC20A1 expression status, showed that low KMT2C expression and high SLC20A1 expression were strongly associated with a high probability of death (pink line). In contrast, high KMT2C and low SLC20A1 expression were strongly associated with a low probability of death (green line; P ¼ .0001; Figure 2 ). The 10-year survival rate for ER þ patients with low KMT2C and high SLC20A1 expression was 0%. In contrast, for ER þ patients with high KMT2C and low SLC20A1 expression, the 10-year survival rate was 86.78% (Table 6 ). 
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The luminal classification was further classified according to the expression of KMT2C and SLC20A1. For KMT2C expression status and luminal subtype, the 65 patients with ER þ luminal subtypes were divided into high/luminal A, low/luminal A, high/ luminal B, and low/luminal B (Table 7) . Similarly, we divided the 65 patients according to SLC20A1 expression status and luminal subtype ( Table 8 ). The mutual information for KMT2C and SLC20A1 was 0.28072 and 0.33481, respectively. The KaplanMeier survival curves for the entire group of 344 patients with ER þ luminal subtypes, stratified by KMT2C expression status and luminal subtype, suggested that low KMT2C expression was associated with shorter survival in both patients with luminal A and those with luminal B breast cancer (P ¼ .0001; Figure 3A ). The 10-year survival rates were 20.50% for luminal A patients with low KMT2C expression ( Figure 3A ; red solid line) and 0% for luminal B patients with low KMT2C expression ( Figure 3A ; Figure 3A ; red solid line) had significantly worse overall survival than luminal A patients with high KMT2C expression ( Figure 3A ; blue solid line). The survival rates at 5 and 10 years were 87.79% and 20.50% for luminal A patients with low KMT2C expression and 94.30% and 74.81% for those with high KMT2C expression, respectively. Luminal B patients with low KMT2C expression ( Figure 3A ; red dotted line) had a greater risk of death than those with high KMT2C expression ( Figure 3A ; blue dotted line). The survival rates at 5 and 10 years were 57.60% and 0% for luminal B patients with low KMT2C expression and 85.02% and 44.17% for those with high KMT2C expression, respectively. The KaplanMeier survival curves for the entire group of 344 patients with the ER þ luminal type, stratified by SLC20A1 expression status and luminal type, demonstrated that high expression of SLC20A1 was strongly associated with shorter survival in both patients with luminal A and those with luminal B breast cancer (P ¼ .0009; Figure 3B ). The 10-year survival rates were 25.50% for luminal A patients with high SLC20A1 expression ( Figure 3B ; blue solid line) and 0% for luminal B patients with high SLC20A1 expression ( Figure 3B ; blue dotted line). Patients with high SLC20A1 expression and luminal A ( Figure 3B ; blue solid line) had significantly worse overall survival compared with those with low SLC20A1 expression and luminal A ( Figure 3B ; red solid line). The survival rates at 5 and 10 years were 90.65% and 25.50% for luminal A patients with high SLC20A1 expression and 89.76% and 66.64% for those with low SLC20A1 expression, respectively. Patients with high SLC20A1 expression and luminal B ( Figure 3B ; blue dotted line) had a greater risk of death than those with low SLC20A1 expression and luminal B ( Figure 3B ; red dotted line). The survival rates at 5 and 10 years were 72.86% and 0% for luminal B patients with high SLC20A1 expression and 76.96% and 76.96% for those with low SLC20A1 expression, respectively. 
Clinical Breast Cancer June 2017 -e139
Discussion
The uncertainty in the prognosis of patients with ER þ breast cancer is very large. However, we found that the uncertainty was reduced by the information of KMT2C and/or SLC20A1 expression. Our study results suggest that the expression levels of KMT2C and SLC20A1 are significantly associated with the differentiation of survival in ER þ breast cancer. We found that low KMT2C expression was associated with a poor outcome, and high SLC20A1 expression was associated with poor outcome. Furthermore, the expression of both KMT2C and SLC20A1 was significantly and strongly associated with the differentiation of survival. KMT2C, a member of the histone lysine methyltransferase family, epigenetically plays an important role in transcriptional regulation. KMT2C is thought to be a tumor suppressor, and deletions of the KMT2C gene have been associated with a poor prognosis in acute myeloid leukemia. 20 Recent studies have also reported that genetic alterations of KMT2C such as somatic mutations were associated with poor outcomes in breast cancer. 21, 22 Thus, KMT2C has been implicated to have a potential role as a tumor suppressor. However, it has also been reported that changes in KMT2C expression had no association with clinicopathologic parameters and prognosis in whole breast cancer. 21, 22 In contrast to those reports, our finding that low KMT2C expression is associated with a poor outcome strongly supports the role of KMT2C as a tumor suppressor. It is also known that KMT2C is a co-regulator of ER and cooperatively regulates gene transcription in an estrogen-dependent manner. [23] [24] [25] In addition, a recent study has shown inactivating mutations in KMT2C are resistant to hormonal therapy. 26 Therefore, the downregulation of KMT2C might specifically lead to hormonal resistance in ER þ breast cancer.
SLC20A1 is a sodium-dependent phosphate transporter that imports phosphate into cells and plays a critical role in maintaining cellular phosphate homeostasis. 27, 28 Although the role of phosphate transporter activity in cancerous progression is unclear, it was reported that SLC20A1 is important in cell proliferation and tumor cell growth in an independent manner by its phosphate transport activity. 29 Therefore, the overexpression of SLC20A1 might promote cancer progression in ER þ breast cancer.
Low KMT2C expression or high SLC20A1 expression was associated with worse survival in luminal B compared with luminal A breast cancer. It has generally been accepted that luminal B cases have a poorer outcome than luminal A cases. 30 However, our subclassification of these patients indicated that luminal A patients with low KMT2C expression experienced worse survival than luminal B patients with high KMT2C expression and that luminal A patients with high SLC20A1 expression experienced worse survival than luminal B patients with low SLC20A1 expression.
Conclusion
The information theoretical analysis is a powerful tool for quantifying clinical behavior in cancer and identifying the important genes underlying those behaviors. We believe that KMT2C and SLC20A1 are powerful prognostic biomarkers in ER þ breast cancer that can distinguish patients with an extremely bad prognosis from those with a sufficiently good prognosis at breast cancer diagnosis. Clinical examination of the expression levels of both KMT2C and SLC20A1 in ER þ breast cancer will be very useful in the determination of prognosis and therapy. Furthermore, analyses for the functional roles, downstream events, and interactions of the altered expression of both genes might reveal novel molecular therapeutic candidates for hormonal resistance in ER þ breast cancer. Clinical Practice Points ER þ luminal breast cancer has been reported to be the most heterogeneous in terms of gene expression, mutation spectrum, copy number changes, and clinical outcomes. One third of patients with ER þ breast cancer will exhibit endocrine therapy resistance, and many patients with ER þ breast cancer will develop recurrence and die 5 to 10 years after diagnosis. In ER þ breast cancer, a major problem is to distinguish those patients most likely to develop recurrence or metastatic disease within 10 years after the breast cancer diagnosis from those with a sufficiently good prognosis. This has brought into sharp relief the need for new prognostic markers that can predict the outcome as accurately as possible at the diagnosis. From our results, the expression of KMT2C and SLC20A1 was significantly associated with the differentiation of survival in ER þ breast cancer. ER þ patients with low KMT2C expression had a greater risk of death than those with high KMT2C expression, and patients with high SLC20A1 expression had a greater risk of death than those with low SLC20A1 expression. 
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Furthermore, the expression of both KMT2C and SLC20A1 was significantly and strongly associated with the differentiation of survival.
The 10-year survival rate for ER þ patients with low KMT2C
and high SLC20A1 expression was 0%. In contrast, for ER þ patients with high KMT2C and low SLC20A1 expression, the 10-year survival rate was 86.78%. Clinical examination of the expression of both KMT2C and SLC20A1 in ER þ breast cancer will be very useful for the determination of prognosis and therapy.
